Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2023 | Advances in GvHD prophylaxis & treatment

Anna Sureda • 4 May 2023
EBMT 2023
General Abatacept Anti-thymocyte globulin Cyclophosphamide

Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, comments on recent advances in strategies to prevent and treat graft-versus-host disease (GvHD) following stem cell transplantation, highlighting the use of post-transplant cyclophosphamide (PTCy), anti-thymocyte globulin (ATG), and abatacept. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Takeda: Consultancy, Honoraria, Research Funding, Speakers Bureau; BMS/Celgene: Consultancy, Honoraria, Research Funding; MSD: Consultancy, Honoraria; Kite: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Jannsen: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; GenMab: Consultancy, Honoraria; Pierre Fabre: Consultancy, Honoraria; Astra Zeneca: Consultancy, Honoraria.

More from Anna Sureda

Overcoming common misconceptions about CAR-T in DLBCL
3:43
Overcoming common misconceptions about CAR-T in DLBCL
Anna Sureda • 18 Mar 2026
Integrating bispecific antibodies into the transplant strategy for B-cell non-Hodgkin lymphomas
2:56
Integrating bispecific antibodies into the transplant strategy for B-cell non-Hodgkin lymphomas
Anna Sureda • 18 Mar 2026
Insights into the EBMT Consensus on transplantation in Hodgkin lymphoma
4:20
Insights into the EBMT Consensus on transplantation in Hodgkin lymphoma
Anna Sureda • 18 Mar 2026
Register for the fast-approaching 52nd Annual Meeting of the EBMT
1:21
Register for the fast-approaching 52nd Annual Meeting of the EBMT
Anna Sureda • 18 Mar 2026

Related Videos

The ethical challenges of AI in hematology: patient communication, trust and regulation
3:12
The ethical challenges of AI in hematology: patient communication, trust and regulation
Adrián Mosquera Orgueira • 24 Sep 2026
The future of AI in hematology: personalized medicine, opportunities and risks
2:30
The future of AI in hematology: personalized medicine, opportunities and risks
Adrián Mosquera Orgueira • 24 Sep 2026
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
5:18
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
Shyam Patel • 13 Oct 2026
The scientific and clinical implications of therapy-related CHIP in oncology
2:43
The scientific and clinical implications of therapy-related CHIP in oncology
Shyam Patel • 13 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals